Resources from the same session
LBA4 - Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study
Presenter: Shusen Wang
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
Slides
Webcast
54O - Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)
Presenter: Valerie Heong
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
Slides
Webcast
Invited Discussant one LBA4 and 54O
Presenter: Shaheenah Dawood
Session: Proffered Paper session: Breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session: Breast cancer
Resources:
Webcast
LBA5 - Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort
Presenter: Xichun Hu
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
Slides
Webcast
55O - Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER+) breast cancer
Presenter: Makiko Ono
Session: Proffered Paper session: Breast cancer
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Proffered Paper session: Breast cancer
Resources:
Webcast